DDOST is associated with tumor immunosuppressive microenvironment in cervical cancer
Abstract Evidence has revealed that DDOST plays an important role in cancer development and progression. However, there are no reports on functions of DDOST in cervical tumorigenesis. Hence, we investigated the relationship of DDOST with prognosis, mutation, promoter methylation, immune cell infiltration, and drug sensitivity using bioinformatics techniques. Our results demonstrated that DDOST was significantly upregulated in a variety of tumor types and correlated with poor prognosis, including cervical cancer. Cox regression analysis dissected that high DDOST expression was associated with poor survival in cervical cancer patients. Immune infiltration analysis defined that DDOST was negatively correlated with CD8 T cells and NK cells. Strikingly, the sensitivity to multiple drugs was negatively correlated with the expression of DDOST. Therefore, our findings uncovered that DDOST could play an essential role in the tumor microenvironment and tumor immune regulation in cervical cancer, which indicated that DDOST could be a useful biomarker for prognosis and a potential therapeutic target for cancer treatment..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Discover oncology - 15(2024), 1 vom: 09. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mei, Jie [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s) 2024 |
---|
doi: |
10.1007/s12672-024-00927-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR055087795 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR055087795 | ||
003 | DE-627 | ||
005 | 20240311094631.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240310s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12672-024-00927-z |2 doi | |
035 | |a (DE-627)SPR055087795 | ||
035 | |a (SPR)s12672-024-00927-z-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Mei, Jie |e verfasserin |4 aut | |
245 | 1 | 0 | |a DDOST is associated with tumor immunosuppressive microenvironment in cervical cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2024 | ||
520 | |a Abstract Evidence has revealed that DDOST plays an important role in cancer development and progression. However, there are no reports on functions of DDOST in cervical tumorigenesis. Hence, we investigated the relationship of DDOST with prognosis, mutation, promoter methylation, immune cell infiltration, and drug sensitivity using bioinformatics techniques. Our results demonstrated that DDOST was significantly upregulated in a variety of tumor types and correlated with poor prognosis, including cervical cancer. Cox regression analysis dissected that high DDOST expression was associated with poor survival in cervical cancer patients. Immune infiltration analysis defined that DDOST was negatively correlated with CD8 T cells and NK cells. Strikingly, the sensitivity to multiple drugs was negatively correlated with the expression of DDOST. Therefore, our findings uncovered that DDOST could play an essential role in the tumor microenvironment and tumor immune regulation in cervical cancer, which indicated that DDOST could be a useful biomarker for prognosis and a potential therapeutic target for cancer treatment. | ||
650 | 4 | |a Cervical cancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a DDOST |7 (dpeaa)DE-He213 | |
650 | 4 | |a TME |7 (dpeaa)DE-He213 | |
650 | 4 | |a Biomarker |7 (dpeaa)DE-He213 | |
650 | 4 | |a Treatment |7 (dpeaa)DE-He213 | |
700 | 1 | |a Pan, Liuliu |4 aut | |
700 | 1 | |a Huang, Min |4 aut | |
700 | 1 | |a Bao, Dandan |4 aut | |
700 | 1 | |a Gao, Hui |4 aut | |
700 | 1 | |a Wang, Danhan |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Discover oncology |d Springer US, 2021 |g 15(2024), 1 vom: 09. März |h Online-Ressource |w (DE-627)SPR055090753 |w (DE-600)3059869-2 |x 2730-6011 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:09 |g month:03 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12672-024-00927-z |z kostenfrei |3 Volltext |
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 15 |j 2024 |e 1 |b 09 |c 03 |